Development of methylation-based biomarkers for breast cancer detection by model training and validation in synthetic cell-free DNA | de Procé SM, et al | bioRxiv | Feb. 2022

de Procé SM, Adamowicz M, Dutta P, Warlow SJ, Moss J, Shemer R, et al. Development of methylation-based biomarkers for breast cancer detection by model training and validation in synthetic cell-free DNA. bioRxiv. 2022;2022-02.

Nonacus products: Oncology

Abstract

Circulating tumour-derived DNA (ctDNA) carries the genetic and epigenetic characteristics of the tumour from which it is derived and can give information about the biology and tissue origins of the underlying tumour. DNA methylation is an epigenetic mark that is specific to individual tissues and, as methylation profiles are disrupted in tumours, they can indicate the tissue of origin and cancer type of ctDNA. We have developed a set of methylation biomarkers for detecting breast cancer in plasma cell-free DNA (cfDNA).

Development of methylation-based biomarkers for breast cancer detection by model training and validation in synthetic cell-free DNA

Cell3 Target,cfDNA,methylation